Exscientia plc. (8/31/23). "Press Release: Exscientia to Present at Upcoming Investor Conferences in September". Oxford.

	Organisation	Exscientia plc (Nasdaq: EXAI)
	Group	Recursion Pharmaceuticals (Group)
	Organisation 2	Wells Fargo Securities LLC
	Product	Wells Fargo Healthcare Conference 2023 Boston
	Product 2	Morgan Stanley Global Healthcare Conference 2023 New York
	Index term	Exscientia–Wells Fargo: investor conference, 202309 supply service Exscientia to present at Wells Fargo Healthcare Conference 2023
	Index term 2	Exscientia–Morgan Stanley: investor conference, 202309 supply service Exscientia to present at Morgan Stanley Annual Global Healthcare Conference 2023
	Person	Sherman, Sara (Exscientia 202109 Investor Relations)
	Person 2	Stohlmann, Oliver (Exscientia 202306 Media Relations)

Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in September:

> 2023 Wells Fargo Healthcare Conference. Fireside chat on Thursday, September 7, 2023, at 3:45 p.m. EDT (8:45 p.m. BST) in Boston, Massachusetts

> Morgan Stanley Global Healthcare Conference 2023. Formal presentation on Tuesday, September 12, 2023, at 8:10 a.m. EDT (1:10 p.m. BST) in New York, NY

Live webcasts will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Investor Relations Contact:
Sara Sherman
investors@exscientia.ai

Media Contact:
Oliver Stohlmann
media@exscientia.ai

Record changed: 2024-01-20